Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin

11/26/2021 | 12:03pm EST


© MT Newswires 2021
All news about OCUGEN, INC.
01/21Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
01/14Gen Z investors shift focus from 'meme-stocks' to the 'metaverse,' report shows
RE
01/13Ocugen, Inc. - COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron and Delta Vari..
AQ
01/12OCUGEN : COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Varian..
PU
01/12OCUGEN, INC. : Other Events (form 8-K)
AQ
01/12Thinking about buying stock in Avalo Therapeutics, AxoGen, Ocugen, BioNano Genomics, or..
PR
01/12Ocugen Says Data Show Covaxin Booster Neutralizes SARS-CoV-2 Omicron, Delta Variants
MT
01/12India's Bharat Biotech says Covaxin booster shot neutralises Omicron
RE
01/12COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of ..
AQ
01/12Ocugen, Inc. and Bharat Biotech Announce Results from a Study Conducted at Emory Univer..
CI
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -53,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -10,9x
Yield 2021 -
Capitalization 653 M 653 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 3,61x
Nbr of Employees 15
Free-Float 97,3%
Chart OCUGEN, INC.
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | OCGN | US67577C1053 | MarketScreener
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 3,28 $
Average target price 10,33 $
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian Chief Financial Officer & Secretary
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.-27.91%653
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508